NCT06730386 - A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

February 26, 2028

Study Completion Date

August 30, 2028

Conditions

Solid Cancer

Interventions

DRUG

AK138D1

Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.

Trial Locations (4)

NOT_YET_RECRUITING

Macquarie University, North Ryde

NOT_YET_RECRUITING

Blacktown Hospital-Blacktwon Cancer and Haematology Centre, Blacktown

RECRUITING

Peninsula & South Eastern Haematology and Oncology Group, Frankston

RECRUITING

ICON Cancer Centre South Brisbane, South Brisbane